Updates in Endoscopic Bariatric and Metabolic Therapies

Hammad Qureshi, Naba Saeed, Manol Jovani, Hammad Qureshi, Naba Saeed, Manol Jovani

Abstract

The rising prevalence of obesity, and related morbidity and mortality, has necessitated the development of therapeutic weight loss strategies. Lifestyle modifications alone have only yielded modest benefit, and while bariatric surgery has shown significant short- and long-term results, only a minority of eligible patients end up receiving this treatment. Endoscopic bariatric and metabolic therapies (EBMTs) are a rapidly evolving field, which provides a less invasive middle ground treatment option for weight loss. Here we discuss the efficacy, as well as short- and long-term outcomes with restrictive, malabsorptive/metabolic and aspiration endoscopic techniques, and their effects on metabolic parameters.

Keywords: endoscopic bariatric and metabolic therapies (EBMTs); obesity; weight loss.

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Stahl J.M., Malhotra S. Obesity Surgery Indications and Contraindications. StatPearls Publishing; Treasure Island, FL, USA: 2018.
    1. Dietz W.H. The response of the US Centers for Disease Control and Prevention to the obesity epidemic. Annu. Rev. Public Health. 2015;36:575–596. doi: 10.1146/annurev-publhealth-031914-122415.
    1. Ward Z.J., Bleich S.N., Long M.W., Gortmaker S.L. Association of body mass index with health care expenditures in the United States by age and sex. PLoS ONE. 2021;16:e0247307. doi: 10.1371/journal.pone.0247307.
    1. Ren M., Zhou X., Zhang Y., Mo F., Yang J., Yu M., Ji F. Effects of Bariatric Endoscopy on Non-Alcoholic Fatty Liver Disease: A Comprehensive Systematic Review and Meta-Analysis. Front. Endocrinol. 2022;13:931519. doi: 10.3389/fendo.2022.931519.
    1. Jirapinyo P., McCarty T.R., Dolan R.D., Shah R., Thompson C.C. Effect of endoscopic bariatric and metabolic therapies on nonalcoholic fatty liver disease: A systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 2021;20:511–524.e1. doi: 10.1016/j.cgh.2021.03.017.
    1. Shah R., Davitkov P., Dayyeh B.K.A., Saumoy M., Murad M.H. AGA technical review on intragastric balloons in the management of obesity. Gastroenterology. 2021;160:1811–1830. doi: 10.1053/j.gastro.2021.02.043.
    1. Abu Dayyeh B.K., Kumar N., Edmundowicz S.A., Jonnalagadda S., Larsen M., Sullivan S., Thompson C.C., Banerjee S. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest. Endosc. 2015;82:425–438.e5. doi: 10.1016/j.gie.2015.03.1964.
    1. O’Brien P.E., Hindle A., Brennan L., Skinner S., Burton P., Smith A., Crosthwaite G., Brown W. Long-term outcomes after bariatric surgery: A systematic review and meta-analysis of weight loss at 10 or more years for all bariatric procedures and a single-centre review of 20-year outcomes after adjustable gastric banding. Obes. Surg. 2019;29:3–14. doi: 10.1007/s11695-018-3525-0.
    1. Popov V.B., Ou A., Schulman A.R., Thompson C.C. The impact of intragastric balloons on obesity-related co-morbidities: A systematic review and meta-analysis. Am. J. Gastroenterol. 2017;112:429–439. doi: 10.1038/ajg.2016.530.
    1. Trang J., Lee S.S., Miller A., Pico C.C., Postoev A., Ibikunle I., Ibikunle C.A. Incidence of nausea and vomiting after intragastric balloon placement in bariatric patients—A systematic review and meta-analysis. Int. J. Surg. 2018;57:22–29. doi: 10.1016/j.ijsu.2018.06.038.
    1. Kotinda A.P.S.T., De Moura D.T.H., Ribeiro I.B., Singh S., Neto A.M.D.P., Proença I.M., Flor M.M., De Souza K.L., Bernardo W.M., De Moura E.G.H. Efficacy of intragastric balloons for weight loss in overweight and obese adults: A systematic review and meta-analysis of randomized controlled trials. Obes. Surg. 2020;30:2743–2753. doi: 10.1007/s11695-020-04558-5.
    1. Bapaye J., Chandan S., Khan S.R., Mohan B.P., Ramai D., Dhindsa B.S., Shah A.R., Saghir S.M., Bilal M., Facciorusso A. Safety and efficacy of adjustable intragastric balloons for treatment of obesity-a systematic review and meta-analysis. Gastrointest. Endosc. 2022;95:AB18. doi: 10.1016/j.gie.2022.04.089.
    1. Abu Dayyeh B.K., Maselli D.B., Rapaka B., Lavin T., Noar M., Hussan H., Chapman C.G., Popov V., Jirapinyo P., Acosta A., et al. Adjustable intragastric balloon for treatment of obesity: A multicentre, open-label, randomised clinical trial. Lancet. 2021;398:1965–1973. doi: 10.1016/S0140-6736(21)02394-1.
    1. Bazerbachi F., Vargas E.J., Rizk M., Maselli D.B., Mounajjed T., Venkatesh S.K., Watt K.D., Port J.D., Basu R., Acosta A., et al. Intragastric balloon placement induces significant metabolic and histologic improvement in patients with nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol. 2021;19:146–154.e4. doi: 10.1016/j.cgh.2020.04.068.
    1. Lee Y.-M., Low H.C., Lim L.G., Dan Y.Y., Aung M.O., Cheng C.L., Wee A., Lim S.G., Ho K.Y. Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: A pilot study. Gastrointest. Endosc. 2012;76:756–760. doi: 10.1016/j.gie.2012.05.023.
    1. Goyal H., Kopel J., Perisetti A., Mann R., Ali A., Tharian B., Saligram S., Inamdar S. Endobariatric procedures for obesity: Clinical indications and available options. Ther. Adv. Gastrointest. Endosc. 2021;14:2631774520984627. doi: 10.1177/2631774520984627.
    1. Dastis S.N., François E., Devière J., Hittelet A., Mehdi A.I., Barea M., Dumonceau J.M. Intragastric balloon for weight loss: Results in 100 individuals followed for at least 2.5 years. Endoscopy. 2009;41:575–580. doi: 10.1055/s-0029-1214826.
    1. Pytraczyk S. Long-Term Maintenance of Weight Loss Following Removal of Intragastric Balloon (IGB) Am. J. Gastroenterol. 2018;113:S439. doi: 10.14309/00000434-201810001-00786.
    1. El Haddad A., Rammal M.O., Soweid A., Sharara A.I., Daniel F., Rahal M.A., Shaib Y. Intragastric balloon treatment of obesity: Long-term results and patient satisfaction. Turk. J. Gastroenterol. 2019;30:461. doi: 10.5152/tjg.2019.17877.
    1. Barola S., Chen Y.I., Ngamruengphong S., Kalloo A.N., Khashab M.A., Kumbhari V. Technical aspects of endoscopic sleeve gastroplasty. VideoGIE. 2017;2:48. doi: 10.1016/j.vgie.2017.01.002.
    1. De Moura D.T.H., de Moura E.G.H., Thompson C.C. Endoscopic sleeve gastroplasty: From whence we came and where we are going. World J. Gastrointest. Endosc. 2019;11:322. doi: 10.4253/wjge.v11.i5.322.
    1. Abu Dayyeh B.K., Acosta A., Camilleri M., Mundi M.S., Rajan E., Topazian M.D., Gostout C.J. Endoscopic sleeve gastroplasty alters gastric physiology and induces loss of body weight in obese individuals. Clin. Gastroenterol. Hepatol. 2017;15:37–43.e1. doi: 10.1016/j.cgh.2015.12.030.
    1. Hedjoudje A., Dayyeh B.K.A., Cheskin L.J., Adam A., Neto M.G., Badurdeen D., Morales J.G., Sartoretto A., Nava G.L., Vargas E., et al. Efficacy and safety of endoscopic sleeve gastroplasty: A systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 2020;18:1043–1053.e4. doi: 10.1016/j.cgh.2019.08.022.
    1. Li P., Ma B., Gong S., Zhang X., Li W. Efficacy and safety of endoscopic sleeve gastroplasty for obesity patients: A meta-analysis. Surg. Endosc. 2020;34:1253–1260. doi: 10.1007/s00464-019-06889-6.
    1. Abu Dayyeh B.K., Bazerbachi F., Vargas E.J., Sharaiha R.Z., Thompson C.C., Thaemert B.C., Teixeira A.F., Chapman C.G., Kumbhari V., Ujiki M.B., et al. Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): A prospective, multicentre, randomised trial. Lancet. 2022;400:441–451. doi: 10.1016/S0140-6736(22)01280-6.
    1. Hajifathalian K., Mehta A., Ang B., Skaf D., Shah S.L., Saumoy M., Dawod Q., Dawod E., Shukla A., Aronne L., et al. Improvement in insulin resistance and estimated hepatic steatosis and fibrosis after endoscopic sleeve gastroplasty. Gastrointest. Endosc. 2021;93:1110–1118. doi: 10.1016/j.gie.2020.08.023.
    1. Jagtap N., Kalapala R., Katakwar A., Sharma M., Aslam M., Gupta R., Rao P.N., Goud R., Tandan M., Kanakagiri H., et al. Endoscopic sleeve gastroplasty—Minimally invasive treatment for non-alcoholic fatty liver disease and obesity. Indian J. Gastroenterol. 2021;40:572–579. doi: 10.1007/s12664-021-01202-7.
    1. Lavín-Alconero L., Fernández-Lanas T., Iruzubieta-Coz P., Arias-Loste M.T., Rodriguez-Duque J.C., Rivas C., Cagigal M.L., Montalbán C., Useros A.L., Álvarez-Cancelo A., et al. Efficacy and safety of endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy in obese subjects with Non-Alcoholic SteatoHepatitis (NASH): Study protocol for a randomized controlled trial (TESLA-NASH study) Trials. 2021;22:756. doi: 10.1186/s13063-021-05695-7.
    1. Multicenter, Randomized, Controlled and Double-blind Study of Efficacy and Safety of Endoscopic Gastric Tubulization in Patients With Non-alcoholic Steatohepatitis (NASH-APOLLO). (NASH-APOLLO) [(accessed on 15 September 2022)]; Available online: .
    1. Fayad L., Adam A., Schweitzer M., Cheskin L.J., Ajayi T., Dunlap M., Badurdeen D.S., Hill C., Paranji N., Lalezari S., et al. Endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy: A case-matched study. Gastrointest. Endosc. 2019;89:782–788. doi: 10.1016/j.gie.2018.08.030.
    1. Novikov A.A., Afaneh C., Saumoy M., Parra V., Shukla A., Dakin G.F., Pomp A., Dawod E., Shah S., Aronne L.J., et al. Endoscopic sleeve gastroplasty, laparoscopic sleeve gastrectomy, and laparoscopic band for weight loss: How do they compare? J. Gastrointest. Surg. 2018;22:267–273. doi: 10.1007/s11605-017-3615-7.
    1. Gu L., Lin K., Du N., Ng D.M., Lou D., Chen P. Differences in the effects of laparoscopic sleeve gastrectomy and laparoscopic Roux-en-Y gastric bypass on gut hormones: Systematic and meta-analysis. Surg. Obes. Relat. Dis. 2021;17:444–455. doi: 10.1016/j.soard.2020.10.018.
    1. Peterli R., Steinert R.E., Woelnerhanssen B., Peters T., Christoffel-Courtin C., Gass M., Kern B., von Fluee M., Beglinger C. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: A randomized, prospective trial. Obes. Surg. 2012;22:740–748. doi: 10.1007/s11695-012-0622-3.
    1. Sharaiha R.Z., Kumbhari V. Are We Moving in the Right Direction by Altering Gastric Motility for Weight Loss? Clin. Gastroenterol. Hepatol. 2020;18:48–50. doi: 10.1016/j.cgh.2019.07.009.
    1. Alqahtani A., Al-Darwish A., Mahmoud A.E., Alqahtani Y.A., Elahmedi M. Short-term outcomes of endoscopic sleeve gastroplasty in 1000 consecutive patients. Gastrointest. Endosc. 2019;89:1132–1138. doi: 10.1016/j.gie.2018.12.012.
    1. Lopez-Nava G., Negi A., Bautista-Castaño I., Rubio M.A., Asokkumar R. Gut and metabolic hormones changes after endoscopic sleeve gastroplasty (ESG) vs. laparoscopic sleeve gastrectomy (LSG) Obes. Surg. 2020;30:2642–2651. doi: 10.1007/s11695-020-04541-0.
    1. Fayad L., Oberbach A., Schweitzer M., Askin F., Voltaggio L., Larman T., Enderle M., Hahn H., Khashab M.A., Kalloo A.N., et al. Gastric mucosal devitalization (GMD): Translation to a novel endoscopic metabolic therapy. Endosc. Int. Open. 2019;7:E1640–E1645. doi: 10.1055/a-0957-3067.
    1. Oberbach A., Schlichting N., Kullnick Y., Heinrich M., Lehmann S., Retschlag U., Friedrich M., Fayad L., Dietrich A., Khashab M.A., et al. Gastric mucosal devitalization improves blood pressure, renin and cardiovascular lipid deposition in a rat model of obesity. Endosc. Int. Open. 2019;7:E1605–E1615. doi: 10.1055/a-0990-9683.
    1. Badurdeen D., Hoff A.C., Hedjoudje A., Adam A., Itani M.I., Farha J., Abbarh S., Kalloo A.N., Khashab M.A., Singh V.K., et al. Endoscopic sleeve gastroplasty plus liraglutide versus endoscopic sleeve gastroplasty alone for weight loss. Gastrointest. Endosc. 2021;93:1316–1324.e1. doi: 10.1016/j.gie.2020.10.016.
    1. De Moura D.T.H., Badurdeen D.S., Ribeiro I.B., da Silva Dantas E.F.M., Thompson C.C., Kumbhari V. Perspectives toward minimizing the adverse events of endoscopic sleeve gastroplasty. Gastrointest. Endosc. 2020;92:1115–1121. doi: 10.1016/j.gie.2020.06.038.
    1. Sullivan S., Swain J.M., Woodman G., Antonetti M., De La Cruz-Muñoz N., Jonnalagadda S.S., Ujiki M., Ikramuddin S., Ponce J., Ryou M., et al. Randomized sham-controlled trial evaluating efficacy and safety of endoscopic gastric plication for primary obesity: The ESSENTIAL trial. Obesity. 2017;25:294–301. doi: 10.1002/oby.21702.
    1. Miller K., Turró R., Greve J.W., Bakker C.M., Buchwald J.N., Espinós J.C. MILEPOST multicenter randomized controlled trial: 12-month weight loss and satiety outcomes after pose SM vs. medical therapy. Obes. Surg. 2017;27:310–322. doi: 10.1007/s11695-016-2295-9.
    1. Singh S., Bazarbashi A.N., Khan A., Chowdhry M., Bilal M., de Moura D.T.H., Jirapinyo P., Thakkar S., Thompson C.C. Primary obesity surgery endoluminal (POSE) for the treatment of obesity: A systematic review and meta-analysis. Surg. Endosc. 2022;36:252–366. doi: 10.1007/s00464-020-08267-z.
    1. Jirapinyo P., Thompson C.C. Gastric plications for weight loss: Distal primary obesity surgery endoluminal through a belt-and-suspenders approach. VideoGIE. 2018;3:296–300. doi: 10.1016/j.vgie.2018.08.002.
    1. Huberty V., Machytka E., Boškoski I., Barea M., Costamagna G., Deviere J. Endoscopic gastric reduction with an endoluminal suturing device: A multicenter prospective trial with 1-year follow-up. Endoscopy. 2018;50:1156–1162. doi: 10.1055/a-0630-1224.
    1. Huberty V., Boskoski I., Bove V., Van Ouytsel P., Costamagna G., Barthet M.A., Devière J. Endoscopic sutured gastroplasty in addition to lifestyle modification: Short-term efficacy in a controlled randomised trial. Gut. 2021;70:1479–1485. doi: 10.1136/gutjnl-2020-322026.
    1. Nyström M., Machytka E., Norén E., Testoni P.A., Janssen I., Homedes J.T., Perez J.C.E., Arau R.T. Aspiration therapy as a tool to treat obesity: 1-to 4-year results in a 201-patient multi-center post-market European registry study. Obes. Surg. 2018;28:1860–1868. doi: 10.1007/s11695-017-3096-5.
    1. Thompson C.C., Abu Dayyeh B.K., Kushnir V., Kushner R.F., Schorr A.B., Aronne L.J., Amaro A., Jaffe D.L., Schulman A.R., Early D., et al. Aspiration therapy for the treatment of obesity: 2–4 year results of the PATHWAY multicenter randomized controlled trial. Surg. Obes. Relat. Dis. 2018;14:S4–S5. doi: 10.1016/j.soard.2018.09.018.
    1. Thompson C.C., Abu Dayyeh B.K., Kushnir V., Kushner R.F., Jirapinyo P., Schorr A.B., Aronne L.J., Amaro A., Jaffe D.L., Schulman A.R., et al. Aspiration therapy for the treatment of obesity: 4-year results of a multicenter randomized controlled trial. Surg. Obes. Relat. Dis. 2019;15:1348–1354. doi: 10.1016/j.soard.2019.04.026.
    1. Thompson C.C., Abu Dayyeh B.K., Kushner R., Sullivan S., Schorr A.B., Amaro A., Apovian C.M., Fullum T., Zarrinpar A., Jensen M.D., et al. Percutaneous gastrostomy device for the treatment of class II and class III obesity: Results of a randomized controlled trial. Am. J. Gastroenterol. 2017;112:447. doi: 10.1038/ajg.2016.500.
    1. Jirapinyo P., de Moura D.T., Horton L.C., Thompson C.C. Effect of aspiration therapy on obesity-related comorbidities: Systematic review and meta-analysis. Clin. Endosc. 2020;53:686–697. doi: 10.5946/ce.2019.181.
    1. Van Baar A.C., Holleman F., Crenier L., Haidry R., Magee C., Hopkins D., Grunert L.R., Neto M.G., Vignolo P., Hayee B.H., et al. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: One year results from the first international, open-label, prospective, multicentre study. Gut. 2020;69:295–303. doi: 10.1136/gutjnl-2019-318349.
    1. Meiring S., Meessen E.C.E., van Baar A.C.G., Holleman F., Nieuwdorp M., Damink S.W.O., Schaap F.G., Vaz F.M., Groen A.K., Soeters M.R., et al. Duodenal mucosal resurfacing with a GLP-1 receptor agonist increases postprandial unconjugated bile acids in patients with insulin-dependent type 2 diabetes. Am. J. Physiol.-Endocrinol. Metab. 2022;322:E132–E140. doi: 10.1152/ajpendo.00337.2021.
    1. Ruban A., Ashrafian H., Teare J.P. The EndoBarrier: Duodenal-jejunal bypass liner for diabetes and weight loss. Gastroenterol. Res. Pract. 2018;2018:7823182. doi: 10.1155/2018/7823182.
    1. Rohde U., Hedbäck N., Gluud L.L., Vilsbøll T., Knop F.K. Effect of the EndoBarrier G astrointestinal L iner on obesity and type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes. Metab. 2016;18:300–305. doi: 10.1111/dom.12603.
    1. Ryder R.E., Yadagiri M., Burbridge W., Irwin S.P., Gandhi H., Bashir T., Allden R.A., Wyres M., Cull M., Bleasdale J.P., et al. EndoBarrier treatment for longstanding type 2 diabetes and obesity: Outcomes one year after EndoBarrier in 90 consecutively treated patients. Pract. Diabetes. 2022;39:13–16a. doi: 10.1002/pdi.2393.
    1. Gollisch K.S.C., Lindhorst A., Raddatz D. EndoBarrier gastrointestinal liner in type 2 diabetic patients improves liver fibrosis as assessed by liver elastography. Exp. Clin. Endocrinol. Diabetes. 2017;125:116–121. doi: 10.1055/s-0042-118961.
    1. Hoffmeister A., Hollenbach M., Prettin C., Gundling F., Schepp W., Seufert J., Stein J., Aberle J., Feisthammel J., Petroff D. Weight-loss endoscopy trial (wet): A multi-center, randomized, controlled trial comparing weight loss in endoscopically implanted duodenal-jejunal bypass liners vs. intragastric balloons vs. a sham procedure. Endoscopy. 2022;54((Suppl. S1)):OP113.
    1. Gersin K.S., Rothstein R.I., Rosenthal R.J., Stefanidis D., Deal S.E., Kuwada T.S., Laycock W., Adrales G., Vassiliou M., Szomstein S., et al. Open-label, sham-controlled trial of an endoscopic duodenojejunal bypass liner for preoperative weight loss in bariatric surgery candidates. Gastrointest. Endosc. 2010;71:976–982. doi: 10.1016/j.gie.2009.11.051.
    1. Machytka E., Bužga M., Zonca P., Lautz D.B., Ryou M., Simonson D.C., Thompson C.C. Partial jejunal diversion using an incisionless magnetic anastomosis system: 1-year interim results in patients with obesity and diabetes. Gastrointest. Endosc. 2017;86:904–912. doi: 10.1016/j.gie.2017.07.009.
    1. Fayad L., Cheskin L.J., Adam A., Badurdeen D.S., Hill C., Agnihotri A., Dunlap M., Simsek C., Khashab M.A., Kalloo A.N., et al. Endoscopic sleeve gastroplasty versus intragastric balloon insertion: Efficacy, durability, and safety. Endoscopy. 2019;51:532–539. doi: 10.1055/a-0852-3441.
    1. Kozłowska-Petriczko K., Pawlak K.M., Wojciechowska K., Reiter A., Błaszczyk Ł., Szełemej J., Petriczko J., Wiechowska-Kozłowska A. The Efficacy Comparison of Endoscopic Bariatric Therapies: 6-Month Versus 12-Month Intragastric Balloon Versus Endoscopic Sleeve Gastroplasty. Obes. Surg. 2022:1–8. doi: 10.1007/s11695-022-06398-x.
    1. Jung S.H., Yoon J.H., Choi H.S., Nam S.-J., Kim K.O., Kim D.H., Kim J.-W., Sohn W., Hyun Y.S., Park C.H., et al. Comparative efficacy of bariatric endoscopic procedures in the treatment of morbid obesity: A systematic review and network meta-analysis. Endoscopy. 2020;52:940–954. doi: 10.1055/a-1149-1862.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit